LOGIN
Intravenous Ketorolac, Acetaminophen, Versus Placebo For Reducing Opioid Use
August 2024
Intravenous Ketorolac, Acetaminophen, Versus Placebo For Reducing Opioid Use
Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:1
Intravenous Ketorolac Substantially Reduces Opioid Use and Length of Stay After Lumbar Fusion: A Randomized Controlled Trial.
Spine (Phila Pa 1976) . 2024 Jan 15;49(2):73-80.Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
178 patients with conditions requiring lumbar fusion were randomized to receive either intravenous ketorolac (n=60), intravenous acetaminophen (n=58), or intravenous placebo (n=60). The primary outcome of interest was in-hospital opioid use up to 72 hours. Secondary outcomes included opioid-related adverse events, incidence of radiographic fusion, length of stay, worst, average, best, and current ...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.